Research programme: Alzheimer's disease therapeutics - NanoAxis
Latest Information Update: 28 Aug 2020
At a glance
- Originator NanoAxis
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Alzheimer's-disease in USA (Parenteral)
- 18 Jul 2016 Research programme: Alzheimer's disease therapeutics - NanoAxis is available - http://www.nanoaxisllc.com/Neuroscience.html
- 18 Jul 2016 Early research in Alzheimer's disease in USA (Parenteral)